# THEMBA II T-Cell Vaccine: Vaccination With saRNA COVID-19 Vaccines

> **NCT05370040** · PHASE1,PHASE2 · TERMINATED · sponsor: **ImmunityBio, Inc.** · enrollment: 60 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** AAHI-SC2 Vaccine
- **BIOLOGICAL:** AAHI-SC3 Vaccine
- **BIOLOGICAL:** EUA or approved vaccine

## Key facts

- **NCT ID:** NCT05370040
- **Lead sponsor:** ImmunityBio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-05-05
- **Primary completion:** 2024-03-11
- **Final completion:** 2024-03-11
- **Target enrollment:** 60 (ACTUAL)
- **Why stopped:** Discontinued prior to enroll in Phase 2
- **Last updated:** 2025-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05370040

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05370040, "THEMBA II T-Cell Vaccine: Vaccination With saRNA COVID-19 Vaccines". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05370040. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*